Supply disruption to Ultiva for injection (remifentanil hydrochloride) until 2018

-filed under: Other
High Priority
 
GlaxoSmithKline Australia (GSK) has advised that new stock of ULTIVA remifentanil will be unavailable in Australia until 2018 (for more information see here).

Alternative suppliers of remifentanil exist and pharmacists should be advised to reach out to all available sources to ensure minimal supply disruption.

Remifentanil is also in short supply in New Zealand with limited alternatives until late October (for more information see here).
Copyright © Australian and New Zealand College of Anaesthetists.